Inventor · disambiguated record
Takahiro Sugimoto
Also filed as: SUGIMOTO TAKAHIRO
33 granted patents·9 pending applications·137 citations·filing 2009–2025
97Inventor score
Top patents by PatentIndex Score
42 records- 0197US10428023B2Heterocyclic compound and use thereofTAKEDA PHARMACEUTICALS CO·Filed 2018·Granted Oct 1, 2019·22 cites·1 claims
- 0296US10584097B2Heterocyclic compound and use thereofTAKEDA PHARMACEUTICALS CO·Filed 2019·Granted Mar 10, 2020·14 cites·1 claims
- 0395US9878989B2Heterocyclic compoundTAKEDA PHARMACEUTICALS CO·Filed 2016·Granted Jan 30, 2018·7 cites·2 claims
- 0494US11440883B2Heterocyclic compound and use thereofTAKEDA PHARMACEUTICALS CO·Filed 2020·Granted Sep 13, 2022·3 cites·1 claims
- 0594US9518042B2Nitrogen-containing heterocyclic compoundTAKEDA PHARMACEUTICALS CO·Filed 2016·Granted Dec 13, 2016·8 cites·2 claims
- 0694US9499516B2Nitrogen-containing heterocyclic compoundTAKEDA PHARMACEUTICALS CO·Filed 2016·Granted Nov 22, 2016·8 cites·2 claims
- 0794US9315458B2Nitrogen-containing heterocyclic compoundTAKEDA PHARMACEUTICAL·Filed 2015·Granted Apr 19, 2016·8 cites·2 claims
- 0893US10087150B2Heterocyclic compoundTAKEDA PHARMACEUTICALS CO·Filed 2017·Granted Oct 2, 2018·5 cites·2 claims
- 0992US10428056B2Heterocyclic compoundTAKEDA PHARMACEUTICALS CO·Filed 2018·Granted Oct 1, 2019·4 cites·2 claims
- 1091US10548899B2Quinazolinone and benzotriazinone compounds with cholinergic muscarinin M1 receptor positive allosteric modulator activityTAKEDA PHARMACEUTICALS CO·Filed 2016·Granted Feb 4, 2020·7 cites·11 claims
- 1191US9868725B2Isoindoline-1-one derivatives as cholinergic muscarinic M1 receptor positive alloesteric modulator activity for the treatment of Alzheimer's diseaseTAKEDA PHARMACEUTICALS CO·Filed 2015·Granted Jan 16, 2018·5 cites·16 claims
- 1290US10323027B22,3-dihydro-4H-1,3-benzoxazin-4-one derivatives as modulators of cholinergic muscarinic M1 receptorTAKEDA PHARMACEUTICALS CO·Filed 2016·Granted Jun 18, 2019·4 cites·6 claims
- 1390US2024109874A1Nitrogen-containing heterocyclic compoundTAKEDA PHARMACEUTICALS CO·Filed 2023·Application pending·0 cites
- 1487US11319286B2Heterocyclic compound and application thereofTAKEDA PHARMACEUTICALS CO·Filed 2018·Granted May 3, 2022·4 cites·10 claims
- 1587US9403802B2Heterocyclic compound and use thereforTAKEDA PHARMACEUTICALS CO·Filed 2013·Granted Aug 2, 2016·12 cites·14 claims
- 1686US10457670B2Isoindoline-1-one derivatives as cholinergic muscarinic M1 receptor positive alloesteric modulator activity for the treatment of Alzheimers diseaseTAKEDA PHARMACEUTICALS CO·Filed 2017·Granted Oct 29, 2019·2 cites·13 claims
- 1786US9789084B2Nitrogen-containing heterocyclic compoundTAKEDA PHARMACEUTICALS CO·Filed 2017·Granted Oct 17, 2017·2 cites·5 claims
- 1886US9789083B2Nitrogen-containing heterocyclic compoundTAKEDA PHARMACEUTICALS CO·Filed 2017·Granted Oct 17, 2017·2 cites·5 claims
- 1986US9775827B2Nitrogen-containing heterocyclic compoundTAKEDA PHARMACEUTICALS CO·Filed 2017·Granted Oct 3, 2017·2 cites·5 claims
- 2086US9675597B2Nitrogen-containing heterocyclic compoundTAKEDA PHARMACEUTICALS CO·Filed 2016·Granted Jun 13, 2017·2 cites·1 claims
- 2186US9662316B2Nitrogen-containing heterocyclic compoundTAKEDA PHARMACEUTICALS CO·Filed 2016·Granted May 30, 2017·2 cites·1 claims
- 2286US9655881B2Nitrogen-containing heterocyclic compoundTAKEDA PHARMACEUTICALS CO·Filed 2016·Granted May 23, 2017·2 cites·1 claims
- 2386US2024360080A1Heterocyclic compound and use thereofTAKEDA PHARMACEUTICALS CO·Filed 2023·Application pending·0 cites
- 2485US10899752B22,3-dihydro-4H-1,3-benzoxazin-4-one derivatives as modulators of cholinergic muscarinic M1 receptorTAKEDA PHARMACEUTICALS CO·Filed 2019·Granted Jan 26, 2021·1 cites·11 claims
- 2584US11655241B2Heterocyclic compound and use thereofTAKEDA PHARMACEUTICALS CO·Filed 2019·Granted May 23, 2023·2 cites·15 claims
- 2684US2022411413A1Nitrogen-containing heterocyclic compoundTAKEDA PHARMACEUTICALS CO·Filed 2022·Application pending·0 cites
- 2782US10208046B2Nitrogen-containing heterocyclic compoundTAKEDA PHARMACEUTICALS CO·Filed 2015·Granted Feb 19, 2019·4 cites·14 claims
- 2881US9777005B2Bicyclic heterocyclic compound containing a substituted pyrrole ringTAKEDA PHARMACEUTICALS CO·Filed 2013·Granted Oct 3, 2017·5 cites·12 claims
- 2980US12421188B2Heterocyclic compound and use thereofTAKEDA PHARMACEUTICALS CO·Filed 2025·Granted Sep 23, 2025·0 cites·19 claims
- 3080US12415782B2Heterocyclic compound and use thereofTAKEDA PHARMACEUTICALS CO·Filed 2025·Granted Sep 16, 2025·0 cites·19 claims
- 3180US12404237B2Method of treating excessive sleepiness and/or cataplexy using n-{2-(([1,1′-biphenyl]-3-yl)methyl)pyrrolidin-3-yl}sulfonamide derivativesTAKEDA PHARMACEUTICALS CO·Filed 2025·Granted Sep 2, 2025·0 cites·19 claims
- 3276US10865200B2Nitrogen-containing heterocyclic compoundTAKEDA PHARMACEUTICALS CO·Filed 2018·Granted Dec 15, 2020·0 cites·3 claims
- 3376US2023063805A1Heterocyclic compound and use thereofTAKEDA PHARMACEUTICALS CO·Filed 2022·Application pending·0 cites
- 3476US2021009572A1Nitrogen-containing heterocyclic compoundTAKEDA PHARMACEUTICALS CO·Filed 2020·Application pending·0 cites
- 3575US2021276949A1Heterocyclic compound and use thereofTAKEDA PHARMACEUTICALS CO·Filed 2021·Application pending·0 cites
- 3669US2018000780A1Nitrogen-containing heterocyclic compoundTAKEDA PHARMACEUTICALS CO·Filed 2017·Application pending·0 cites
- 3755US12358879B2Heterocyclic compoundTAKEDA PHARMACEUTICALS CO·Filed 2020·Granted Jul 15, 2025·0 cites·15 claims
- 3852US12091410B2Heterocyclic compoundTAKEDA PHARMACEUTICALS CO·Filed 2019·Granted Sep 17, 2024·0 cites·13 claims
- 3952US2023120205A1Nerve cell degeneration inhibitorUNIV KYOTO·Filed 2021·Application pending·0 cites
- 4051US12071434B2Heterocyclic compoundTAKEDA PHARMACEUTICALS CO·Filed 2019·Granted Aug 27, 2024·0 cites·14 claims
- 4151US2010094000A1Pyrazole compoundsTAKEDA PHARMACEUTICAL·Filed 2009·Application pending·0 cites
- 4246US10131653B2Heterocyclic compoundTAKEDA PHARMACEUTICALS CO·Filed 2016·Granted Nov 20, 2018·0 cites·12 claims
Join the waitlist — get patent alerts
Get an alert when Takahiro Sugimoto files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →